Evidence map›Paper›PMID 30611251›Full record

ArticleHarm reduction journal2019

Underreported injection drug use and its potential contribution to reported increase in sexual transmission of HIV in Kazakhstan and Kyrgyzstan.

Anna P Deryabina, Padmaja Patnaik, Wafaa M El-Sadr

Open access · goldAbstract read
In one paragraph

Article in Harm reduction journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Characterization of HIV-1 Epidemic in Kyrgyzstan.Frontiers in microbiology · 2021
    Article
  14. Review
  15. Determinants of COVID-19 Vaccine Uptake Among People Living with Human Immunodeficiency Virus.Journal of the International Association of Providers of AIDS Care
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Anna P DeryabinaICAP at Columbia University, 34/1 Samal -3, Almaty, 050051, Kazakhstan. annaderyabina@icap.kz.ORCID 0000-0002-0640-890X
Padmaja PatnaikICAP at Columbia University, Allan Rosefield Building, 722 West 168th Street, Room 1310, New York, NY, USA.
Wafaa M El-SadrICAP at Columbia University, Allan Rosefield Building, 722 West 168th Street, Room 1310, New York, NY, USA.
ICAP Global HealthKazakhstan Medical University · KZ

Funding

STRENGTHENING HIV STRATEGIC INFORMATION ACTIVITIES IN THE CENTRAL ASIAN REPUBLICSU2GPS003031 · PS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PATNAIK, PADMAJA · 2010 to 2015
$5.0M
CDC HHS 5U2GPS003031NCHHSTP CDC HHS U2G PS003031
6 · The paper itself

Abstract

backgroundWe conducted a cross-sectional integrated bio-behavioral survey among sex partners of persons who inject drugs (PWID) to explore reasons for reported increase in reporting of heterosexually transmitted HIV in Kazakhstan and Kyrgyzstan.

methodsSexual partners of PWID were recruited through PWID. Behavioral data were collected through semi-structured interviews. Dried blood spots were obtained and tested for HIV and hepatitis C virus antibodies (HCVAb). Descriptive univariate and bivariate analyses, and multivariate analyses using logistic regression modeling were performed to identify factors associated with HIV and HCV infections.

resultsAmong 1982 sex partners of PWID, overall HIV prevalence was 6.4%; 5.1% and 12.9% among those reported never and ever injecting drugs, respectively (p < 0.001). Overall, HCVAb prevalence was 21.3%; 15.0% and 53.9% among those reported never and ever injecting drugs, respectively (p < 0.001). Of HCV-positive participants, 58% and 34% (p < 0.001) reported prior history of injecting drug use among men and women, respectively. HIV prevalence was lower among HCV-negative (4.2%) compared to HCV-positive participants (14.4%) (p < 0.001). HIV prevalence was 3.5% (95%CI = 2.4-4.6) in a subset of female participants with no reported prior injecting drug use history and who were HCVAb-negative and did not report having an HIV-positive sex partner. Participant sex and number of sex partners as well as use of condoms in the past 12 months were not associated with HIV seropositivity.

conclusionsHigh prevalence of HCV among sex partners of PWID who denied ever injecting drugs suggests underreporting of injecting practices. The increased attribution of HIV infection to sexual transmission based on self-report may be partly explained by underreporting of injection drug use due to stigmatization of this behavior.

Indexed as

AdolescentAdultAgedCondomsCross-Sectional StudiesDisease NotificationFemaleHepatitis CHepatitis C AntibodiesHIV InfectionsHumansKazakhstanKyrgyzstanMaleMiddle AgedPrevalenceHepatitis C AntibodiesHepatitis CHIVPeople who inject drugsPWIDSex partnersSexual transmission

Identifiers

PMID30611251
PMCPMC6321689
OpenAlexW2913867913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.